PF 6650833

Drug Profile

PF 6650833

Alternative Names: PF-06650833; PF-6650833

Latest Information Update: 21 Dec 2016

Price : $50

At a glance

  • Originator Pfizer
  • Class
  • Mechanism of Action Interleukin-1 receptor-associated kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Rheumatoid arthritis
  • Phase I Lupus vulgaris

Most Recent Events

  • 01 Nov 2016 Phase-II clinical trials in Rheumatoid arthritis (Treatment-experienced) in USA (PO) (NCT02996500)
  • 01 Oct 2016 Pfizer completes a phase I trial in Healthy volunteers in Japan (PO, Controlled-release) (NCT02936154)
  • 01 Aug 2016 Phase-I clinical trials in Lupus (In volunteers) in Japan (PO, Controlled-release) (NCT02936154)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top